Shamburg News · 8-K filed Oct 22, 2026, 5:28 PM EDT
PAVmed Subsidiary Lucid Diagnostics Closes $15.0 Million Series C Preferred Stock Offering
PAVM · PAVmed Inc.
- Financing
- Material agreement
- Materiality: medium
Effective October 21, 2026, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., entered into subscription agreements with accredited investors for 15,000 shares of newly designated Series C Convertible Preferred Stock at $1,000 per share. The closing occurred the same day with gross proceeds of $15.0 million. Lucid Diagnostics also filed a Certificate of Designations with Delaware and entered into a registration rights agreement covering resale of underlying common stock.
Source: SEC EDGAR, Form 8-K, Items 1.01, 3.03, 5.03, 9.01, accession 0001493152-26-048138.
Written from the filing by Shamburg Markets. Figures are as reported by the company.